Where is Innoviva (INVA) Headed According to Analysts?
Innoviva, Inc. (NASDAQ:INVA) is one of the best affordable biotech stocks to invest in now. On August 11, H.C.
Innoviva Inc. (INVA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 4,586,932 | $83,711,509 | -4% | 0.11% |
| 2. | Sarissa Capital Management Alex Denner | 2,816,022 | $51,392,402 | 28.49% | |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,358,633 | $43,045,052 | +39% | 0.03% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,651,711 | $30,143,728 | +24% | 0.03% |
| 5. | Millennium Management Israel Englander | 1,641,315 | $29,953,999 | -18% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.13 | 62,000 | $814,196.40 | 7,277,000 | 2023-06-15 | Filing | |
| $13.05 | 8,000 | $104,384.00 | 7,215,000 | 2023-06-06 | Filing | |
| $13.04 | 7,000 | $91,296.80 | 7,207,000 | 2023-06-05 | Filing | |
| $13.01 | 120,000 | $1,560,648.00 | 7,200,000 | 2023-05-30 | Filing | |
| $13.12 | 30,000 | $393,729.00 | 7,080,000 | 2023-05-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.52 | 1,196,746 | $20,964,237.40 | 5,658,705 | 2025-03-06 | Filing | |
| $17.63 | 270,374 | $4,766,125.83 | 6,855,451 | 2025-03-05 | Filing | |
| $17.63 | 151,175 | $2,665,079.19 | 7,125,825 | 2025-03-04 | Filing | |
| $13.97 | 5,405 | $75,507.85 | 40,158 | 2023-11-15 | Filing | |
| $14.01 | 5,589 | $78,301.89 | 45,563 | 2023-11-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,436,812 | $172,221,821 | 0% | |
| 2. | 7,097,346 | $129,526,566 | 0% | |
| 3. | 4,330,353 | $79,034,085 | 0.02% | |
| 4. | 67,396,000 | $65,891,287 | 0.44% | |
| 5. | 2,556,972 | $46,664,739 | 0% |
News See All
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
10 Stocks with Insanely High PE Ratios Insiders Are Selling
The U.S. stock market has turned into a theater of extremes right now.
12 Best Extremely Profitable Stocks to Buy
In this piece, we will take a look at 12 best extremely profitable stocks to buy.
11 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we will take a look at the 11 most undervalued biotech stocks to buy according to hedge funds.
5 Cheap Biotech Stocks To Buy
Since the company's July 2021 IPO, CRISPR Therapeutics AG (NASDAQ:CRSP) shares have fallen by 44%.
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds.
Hedge Fund and Insider Trading News: Carl Icahn, Warren Buffett, Bill Ackman, Ray Dalio, Elliott Management, Assurant Inc. (AIZ), Innoviva Inc (INVA), and More
Billionaire investor Carl Icahn has been a hard-charging shareholder activist for decades.
Is INVA A Good Stock To Buy According To Hedge Funds?
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth ...
Innoviva, Inc. (INVA): Hedge Funds Are Cautiously Waiting On The Sidelines
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...